Pancreatic Cancer
A Phase II Study of Preoperative Gemcitabine and Erlotinib Plus Pancreatectomy and Postoperative Gemcitabine and Erlotinib for Patients with Operable Pancreatic Adenocarcinoma
Eligibility Criteria (per Protocol dated 05/29/2009):
- Cytologic or histologic proof of adenocarcinoma of the pancreatic head or uncinate process. NOTE: Subjects with tumors of the pancreatic neck, body or tail are not eligible. Subjects with evidence of neuroendocrine tumors, duodenal adenocarcinoma, or ampullary adenocarcinoma are not eligible.
- Localized, potentially resectable tumors, as defined by the protocol. All subjects must be staged with a chest X-ray or CT, and abdominal CT (contrast-enhanced, helical thin-cut) or MRI. Radiological resectability is defined by specific protocol criteria.
- ECOG/Zubrod Performance status of 0 or 1.
- Subject must have adequate organ function, as determined by the protocol.
- No hiostory of prior EGFR targeted therapy or therapy for pancreatic cancer.
- No active infection requiring intravenous antibiotics at the time of registration.
- Females will not be able to participate if there is pregnancy, or if they have been breastfeeding at the time of study entry.
- No prior malignancy within 5 years of registration (exceptions: non-melanoma skin cancer, in situ cancers).
- Other criteria, as determined by the protocol.
For information about this study, please contact Robin Stewart, RN, PhD, CCRC at (863) 904-1877.